Business
NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026
TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a company developing advanced artificial intelligence solutions for clinical trial optimization and precision medicine, today announced that senior management will open the market at the Toronto Stock Exchange on May 5, 2026. The market open ceremony follows a period of sustained momentum as NetraMark continues to advance its proprietary NetraAI platform
About this update from Netramark Holdings Inc
[{"type":"image","alt":"NetraMark Holdings Inc.","displaySize":"","headline":null,"caption":"NetraMark Holdings Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":94,"url":"https://media.zenfs.com/en/globenewswire.com/192769f9f65e10ea97c7137b2337b7be"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cKmM3wfaRebYT3SszZY1sQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMg--/https://media.zenfs.com/en/globenewswire.com/192769f9f65e10ea97c7137b2337b7be","width":300,"height":94}},"lazy":false},{"type":"text","content":"TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a company developing advanced artificial intelligence solutions for clinical trial optimization and precision medicine, today announced that senior management will open the market at the Toronto Stock Exchange on May 5, 2026.","length":369,"tagName":"p"},{"type":"text","content":"The market open ceremony follows a period of sustained momentum as NetraMark continues to advance its proprietary NetraAI platform and expand its presence across clinical development programs, including recent collaborations in oncology and other therapeutic areas. To see the market opening by NetraMark on May 5 at 9:30 AM ET, viewers can watch live at https://youtube.com/live/EXVhrlnhicU?feature=share.","length":406,"tagName":"p"},{"type":"text","content":"The Company’s participation in the market open ceremony highlights its ongoing engagement with the broader investment community.","length":128,"tagName":"p"},{"type":"text","content":"NetraAI applies advanced mathematical and machine learning approaches to identify clinically meaningful patient subgroups most likely to benefit from treatment, supporting improved trial design and patient selection decisions. By leveraging NetraAI to analyze small, heterogeneous datasets to reveal true patient structure, NetraMark seeks to enable a shift beyond population-level analysis toward interpretable, data-driven patient stratification.","length":448,"tagName":"p"},{"type":"text","content":"About NetraAI","length":13,"tagName":"p"},{"type":"text","content":"NetraAI is engineered to include focus mechanisms that separate small datasets into explainable and unexplainable subsets. Unexplainable subsets are collections of patients that can lead to suboptima...